haloperidol decanoate has been researched along with Parkinson Disease, Secondary in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gedzior, JS; Matthew, BJ | 1 |
| Egan, MF; Hyde, TM; Kleinman, JE; Weinberger, DR; Wing, LL; Wyatt, RJ | 1 |
| Dhopesh, V; Gamble, G; Maany, I; Macfadden, A | 1 |
| Cookson, JC | 1 |
1 trial(s) available for haloperidol decanoate and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Side effects during long-term treatment with depot antipsychotic medication.
Topics: Akathisia, Drug-Induced; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; Fluphenazine; Haloperidol; Humans; Parkinson Disease, Secondary; Psychomotor Agitation; Recurrence; Schizophrenia | 1991 |
3 other study(ies) available for haloperidol decanoate and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate.
Topics: Adult; Amphetamine-Related Disorders; Diphenhydramine; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Humans; Injections, Intramuscular; Male; Methamphetamine; Neural Pathways; Nucleus Accumbens; Parkinson Disease, Secondary; Patient Admission; Patient Readmission; Psychotic Disorders; Receptors, Dopamine D2; Substance Abuse Treatment Centers; Substance Abuse, Intravenous; Substantia Nigra; Treatment Refusal | 2015 |
Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 1995 |
Absence of parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cocaine; Comorbidity; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; Long-Term Care; Male; Middle Aged; Neurologic Examination; Opioid-Related Disorders; Parkinson Disease, Secondary; Receptors, Dopamine; Risk Factors; Schizophrenia | 1997 |